Anti-diabetes therapy: safety considerations for patients with impaired kidney function

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) is a significant risk factor for chronic kidney disease (CKD).
• Kidney function impacts glucose metabolism, affecting insulin resistance and gluconeogenesis.
• Impaired kidney function alters glucose dynamics and complicates antihyperglycemic treatment strategies.

Purpose of the Study:

• To review the impact of kidney disease on glycemic control in T2DM patients.
• To discuss the challenges in antihyperglycemic medication management for T2DM with CKD.
• To provide guidance on the safe use of antihyperglycemic drug classes in this population.

Main Methods:

• Literature review of antihyperglycemic agents in T2DM patients with varying degrees of kidney function.
• Analysis of pharmacokinetic and pharmacodynamic changes affecting drug efficacy and safety.
• Evaluation of risks, including hypoglycemia and reduced drug clearance.

Main Results:

• Appropriate glycemic control can mitigate the progression of kidney dysfunction in T2DM.
• Reduced drug clearance in CKD necessitates dosage adjustments for many antihyperglycemic medications.
• Sulfonylureas pose an increased risk of hypoglycemia in patients with impaired kidney function.

Conclusions:

• Careful selection and dosing of antihyperglycemic drugs are crucial for T2DM patients with CKD.
• Understanding the interplay between kidney function and glucose metabolism is vital for effective treatment.
• Specific antihyperglycemic classes require heightened caution in patients with coexisting T2DM and kidney disease.